Why the study?
Evaluating efficacy of novel compounds in NAFLD and NASH models relies on histological feature scores assigned by a trained pathologist, which the authors sought to automate using convolutional neural networks.
Deep learning with CNNs can automate histopathological scoring of NASH models with good agreement to human pathologists, providing a continuous, high-resolution readout.
Automated NAFLD/NASH histology scoring is feasible; leaves open prospective validation before clinical or research adoption.
Non-alcoholic fatty liver disease (NAFLD) and the progressive form of non-alcoholic steatohepatitis (NASH) are diseases of major importance with a high unmet medical need. Efficacy studies on novel compounds to treat NAFLD/NASH using disease models are frequently evaluated using established histological feature scores on ballooning, inflammation, steatosis and fibrosis. These features are assessed by a trained pathologist using microscopy and assigned discrete scores. We demonstrate how to automate these scores with convolutional neural networks (CNNs). Whole slide images of stained liver sections are analyzed using two different scales with four CNNs, each specialized for one of four histopathological features. A continuous value is obtained to quantify the extent of each feature, which can be used directly to provide a high resolution readout. In addition, the continuous values can be mapped to obtain the established discrete pathologist-like scores. The automated deep learning-based scores show good agreement with the trainer - a human pathologist.
No takes yet. Share an insight, caveat, or question.
Heinemann et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: